Nanomedicines in the treatment of chronic hepatitis C – focus on pegylated interferon alpha-2a

References

• AlgranatiNESySModiM1999A branched methoxy 40 kDa polyethylene glycol (PEG) moiety optimises the pharmacokinetics (PK) of peg interferon a-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC)Hepatology40190
   Google Scholar
• AlterMJKruszon-MoranDNainanOV1999The prevalence of hepatitis C virus infection in the united states, 1988 through 1994N Engl J Med3415566210451460
   PubMed Web of Science ®Google Scholar
• AnnemansLWarieHNechelputM2004A health economic model to assess the long term effectiveness of PEG IFN alpha-2a in hepatitis C infected patientsGastroenterol Belg6718
   PubMed Web of Science ®Google Scholar
• BailonPPalleroniASchafferCA2001Rational design of a potent long lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis CBioconjug Chem1219520211312680
   PubMed Web of Science ®Google Scholar
• BailonPSpenceCSchafferCA1999Pharmacokinetic properties of five polyethylene glycol conjugates of interferon alfa-2aAntivir Ther427
   Google Scholar
• Bogunia-KubikKSugisakaM2002From molecular biology to nanotechnology and nanomedicineBiosystems631233812069723
   PubMed Web of Science ®Google Scholar
• [CDC] Centers for Disease Control and Prevention1998Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV related diseaseMMWR Morb Mortal Wkly Rep471409450721
   PubMedGoogle Scholar
• CooksleyGFosterGGreenJ2000The effect of successful antiviral therapy on health related quality of life for patients with chronic hepatitis C and cirrhosisGastroenterology11895110784595
   PubMed Web of Science ®Google Scholar
• DavisGLAlbrightJECookS1998Projecting the future health care burden from hepatitis C in the united statesHepatology28390A
   Web of Science ®Google Scholar
• DelgadoCFrancisGEFisherD1992The uses and properties of PEG linked proteinsCrit Rev Ther Drug Carrier Syst92493041458545
   PubMed Web of Science ®Google Scholar
• [EASL] European Association for the Study of the Liver1999International Consensus Conference on Hepatitis. Consensus statementJ Hepatol309566110365827
   PubMedGoogle Scholar
• Editorial2004Nanomedicine: grounds for optimism, and a call for papersThe Lancet36293856734
   Web of Science ®Google Scholar
• FriedMWShiffmanMLReddyKR2001Pegylated interferon alfa-2a (Pegasys) in combination with ribavarin: efficacy and safety results from phase 3 randomised actively controlled multicentre studyGastroenterology120A55
   Web of Science ®Google Scholar
• Friedrich-RustMZeuzemSSarrazinC2005Current therapy for hepatitis CInt J Colorectal Dis211915947936
   PubMed Web of Science ®Google Scholar
• FungWJPorterJEBailonP1997Strategies for the preparation and characterisation of poly(ethylene glycol) vinyl sulfonePolym Prepr385656
   Google Scholar
• HeathcoteEJPockrosPJFriedMW1999the pharmacokinetics of pegylated-40 K interferon alpha-2a (PEG-IFN) in chronic hepatitis C (CHC) patients with cirrhosisGastroenterology11673510029632
   PubMed Web of Science ®Google Scholar
• HeathcoteEJShiffmanMLCooksleyWG2000Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosisN Engl J Med34316738011106716
   PubMed Web of Science ®Google Scholar
• ModiMWFriedMWReindollarRW2000The pharmacokinetic behaviour of pegylated (40 kDa) interferon alfa-2a (PEGASYS) in chronic hepatitis C after multiple dosingHepatology32394A10915748
   PubMed Web of Science ®Google Scholar
• OlsonKGehantRMukkuV1997Preparation and characterisation of poly(ethylene glycol)ylated human growth hormone antagonistHarrisJMZaplipskySSan FranciscoAmerical Chemical Society17081
   Google Scholar
• PockrosPJHeathcoteEJShiffmanM2000Efficacy of pegylated (40 kDa) interferon alfa-2a (Pegasys) in randomised trials of patients with chronic hepatitis C, with and without cirrhosis: correlation of virological and histiological responses with baseline liver histology and genotypeHepatology32442A10960282
   PubMed Web of Science ®Google Scholar
• RasenackJZeuzemSFenmanSV2000Therapy with pegylated (40 kDa) interferon alfa-2a (PEGASYS) significantly enhances quality of life compared with standard interferon alfa-2a (ROFERON-A) in patients with chronic hepatitisHepatology32307A
   Web of Science ®Google Scholar
• ReddyKRModiMWPedderS2002Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis CAdv Drug Deliv Rev545718612052715
   PubMed Web of Science ®Google Scholar
• ReddyKRWrightTLPockrosPJ2001Efficacy and safety of pegylated (40 kD) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis CHepatology33433811172346
   PubMed Web of Science ®Google Scholar
• ShermanMDusheikoGMHaussingerD2000Superior virological response in genotype 4 chronic hepatitis C patients treated with pegylated (40 kDa) interferon alfa-2a (Pegasys) compared with standard interferonHepatology32349A
   Google Scholar
• [WHO] World Health Organization1999Consultation, global surveillance and control of hepatitis. Report of WHO consultation organized in collaboration with the viral hepatitis prevention board. Antwerp, BelgiumJ Viral Hepatol63547
   Google Scholar
• XuZXPatelIJoubertP1998Single dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated interferon (PEG-IFN) and interferon alpha-2a (IFN alpha-2a) to healthy subjectsHepatology28702
   Web of Science ®Google Scholar
• YamaokaTTabataYIkadaY1994Distribution and tissue uptake of poly (ethylene glycol) with different molecular weights after intravenous administration to miceJ Pharm Sci8360168046623
   PubMed Web of Science ®Google Scholar
• ZeuzemSFeinmanSVRasenackJ2000Peginterferon alpha-2a in patients with chronic hepatitis CN Engl J Med34316667211106715
   PubMed Web of Science ®Google Scholar